TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company
Transcenta, biologics, antibody
30 Oct, 2019
The FDA last year pulled together the best people from among a number of agencies to try to figure out what could be done about perpetual drugs shortages that create dangers for patients and struggles for doctors and hospitals. After a year of study, its conclusion is that the subject needs more study.
The FDA Tuesday dropped its report Drug Shortages: Root Causes and Potential Solutionswith the explanation that includes suggestions that might help relieve chronic shortages but acknowledging that there has never really been any “private- or public-sector effort to collect and analyze comprehensive information to characterize shortages, quantify their effects, or closely observe the contracting practices that may be driving them.”